In the upcoming Year of the Loong, prosperity is anticipated, as the Dragon spreads its wings. Evopoint Biosesciences Co., Ltd. (hereinafter referred ...
More
On September 10, 2024, Evopoint Biosesciences Co., Ltd. was informed by CDE of NMPA that the EZH2 inhibitor XNW5004 has officially been designated as ...
More
On June 14, 2024, XNW27011, a new-generation Antibody-Coupled Drug (ADC) developed by Evopoint, has been granted Fast Track Designation (FTTD) statu...
More
Evopoint independently developed a new small molecule selective URAT1 inhibitor, XNW3009.
More
Suzhou, China — April 6, 2023 — Evopoint Biosesciences Co., Ltd.(“Evopoint”), a biopharmaceutical company focused on discovering and developing innova...
More
Follow us
